Skip to main content

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Bard Hernia Mesh Trial Rescheduled To October 16, 2023

Introduction

The third bellwether trial concerning accusations that the Bard PerFix Plug is defectively built and caused unpleasant problems following hernia surgery has been rescheduled to begin on October 16, 2023, by the United States District Court presiding over all Bard hernia mesh litigation.

The case was scheduled to begin in May 2023, as the third in a series of early trial dates meant to assist the parties judge how jurors are likely to respond to specific evidence and testimony that would be duplicated across more than 18,000 claims filed against C.R. Bard in a federal MDL (multidistrict litigation).

The judge has already presided over two MDL bellwether trials, which ended with mixed results. The first case went before a jury in August 2021, resulting in a defense verdict for Bard. That trial was followed by a second bellwether case that went before a jury in April 2022, resulting in a $255,000 verdict.

In August 2022, a state court lawsuit in Rhode Island resulted in a $4.8 million verdict over Bard hernia mesh problems, which sent a strong signal to the manufacturer about the extent of liability it may face in certain cases, as each lawsuit goes before a jury.

Each hernia mesh complaint makes similar claims, claiming that people had difficulties with various polypropylene products offered in recent years, such as the Bard PerFix Plug, Bard Ventralight, Bard Ventralex, Bard 3DMax, and other similar systems.

Because the charges raise comparable factual and legal issues, the lawsuit has been centralized and consolidated before the U.S. District Court since August 2018, for coordinated discovery and pretrial procedures. Yet, as fresh hernia mesh claims are filed and the devices continue to fail, the size of the MDL grows.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

NC to Get $150M to Boost Opioid Treatment, Recovery

Categories: Opioids

North Carolina will receive an additional $150 million from Purdue Pharma and the Sackler family as part of a national $7.4 billion settlement related to the opioid

SRI Gets FDA OK for High-Dose Naloxone Trial

Categories: Opioids

SRI has received authorization from the U.S. Food and Drug Administration (FDA) to begin Phase 1 clinical trials of a new, high-dose injectable naloxone formulation.

The approval was granted under an Investigational New Drug (IND)…

Spokane County to Get $5M in New Opioid Settlement

Categories: Opioids

Jurisdictions within Spokane County are set to receive nearly $4.7 million as part of a sweeping $7.4 billion nationwide settlement with Purdue Pharma and its owners, the Sackler family.

The agreement addresses the company’s role in fueling…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!